approved glp 1 agonists Holding GLP-1 Prior to Elective Procedures Upcoming wave of hormone-based therapies

Description

Finan et al

According to Sinha et al., tirzepatide has better efficacy compared to many glucose-lowering medications such as dulaglutide, glargine, semaglutide, and insulin degludec and placebo drugs [14]

These cells release the recruiting chemokine CCL-2

This finding is particularly significant as it demonstrates that the cardiovascular benefits of GLP-1 agonists extend beyond their glucose-lowering effects to encompass direct cardiovascular protection in obesity

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus